Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Deerfield Management Further Raises Its Position in Auspex Pharmaceuticals Inc (ASPX)

James E. Flynn’s Deerfield Management, in a filing with the Securities and Exchange Commission, reported further raising its stake Auspex Pharmaceuticals Inc (NASDAQ:ASPX). The fund bought 700,000 shares at a price of $12 apiece, and currently owns around 1.99 million shares of the common stock of Auspex Pharmaceuticals, Inc.

Auspex

Earlier, Deerfield Management revealed owning 1.29 million common shares of Auspex Pharmaceuticals Inc (NASDAQ:ASPX), which were held via class E preferred stock.

Auspex Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of medicines for the treatment of orphan diseases. Last week the company completed its IPO of 8.1 million shares of its common stock at a price of $12.0 per share.

Last month, Auspex Pharmaceuticals, Inc. raised financing worth $35.0 million through two different debt instruments. Funds worth $20.0 million were led by Deerfield Management Company and supported by other shareholders of the company. Another $15.0 million, in form of a four-year venture loan were raised from Oxford Finance LLC.

Deerfield Management is a healthcare focused investment company and it specializes in funding R&D, managing hostile takeovers, corporate transitions and financial advisory services.

Early this month, Deerfield Management initiated position in KaloBios Pharmaceuticals Inc., (NASDAQ:KBIO). The fund now holds approximately 3.18 million shares, amassing a stake of 9.64% of the company common stock. Deerfield Management also revealed a position in Cara Therapeutics Inc. (NASDAQ:CARA) a couple of days ago. The fund now holds 350,000 shares of Cara Therapeutics Inc., which is equivalent to 1.55% of the company’s common stock.

Disclosure: none

Recommended reading:

Iroquois Capital Edges up Stake in National Holdings Corporation (NHLD)

Cannell Capital Boosts its Stake in ZipRealty, Inc. (ZIPR)

Apple Inc. (AAPL) & Google Inc (GOOG) Are Among Largest Holdings in Columbus Circle Investors’ Latest 13F

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.